Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

The maker of Ozempic and Wegovy has declared war on “fake” copycat weight-loss jabs as it battles a sales slowdown.

Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--had been in short supply as the company raced to increase production and meet surging demand. But the drug came off ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Novo Nordisk, the maker of Wegovy, will focus on commercial strategy and cost reduction. This decision follows a profit ...